Martin Shkreli: once-celebrated investor-turned-pharma executive known for pricing controversies and subsequent regulatory/legal battles.
Regulators have moved to hold Martin Shkreli in contempt for violating a lifetime ban from the pharmaceutical industry, with filings alleging continued stock trading and public commentary since his 2022 release. The action seeks profits from pharma trades and escalating consequences for future violations.